What is JBIO's depreciation?

JBIO (JBIO) reported depreciation of $9K in Q1 2026.

How has JBIO's depreciation changed year-over-year?

JBIO's depreciation increased by 125.0% year-over-year, from $4K to $9K.

What is the long-term trend for JBIO's depreciation?

Over 4 years (2021 to 2025), JBIO's depreciation has grown at a 14.7% compound annual growth rate (CAGR), from $15K to $26K.

JBIO JBIO Depreciation

Depreciation at other companies

Vor BiopharmaVOR

——

Janux TherapeuticsJANX

——

Apogee Therapeutics, Inc.APGE

——

Adaptive BiotechnologiesADPT

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's depreciation?: JBIO (JBIO) reported depreciation of $9K in Q1 2026.
How has JBIO's depreciation changed year-over-year?: JBIO's depreciation increased by 125.0% year-over-year, from $4K to $9K.
What is the long-term trend for JBIO's depreciation?: Over 4 years (2021 to 2025), JBIO's depreciation has grown at a 14.7% compound annual growth rate (CAGR), from $15K to $26K.